ElhofyVice President of Product Research and Collaborations, Cour Pharmaceutical

Dr. Adam Elhofy has over 14 years of scientific research experience in the areas of immunology, neuroscience, and oncology, with multiple publications and grants. He was funded by both the National Institutes of Health and the Multiple Sclerosis society as an investigator at Northwestern University Medical School. He has served in various roles from Principal Investigator of a Nanotech start-up to Chief Science officer. He developed the core technology for the Cell-Ess® line of products and aided in creating patents around novel uses of materials.

His doctoral research won him the award of the Top 5 trainee scientists by the American Association of Immunologists. Dr. Elhofy has 15 scientific publications in peer reviewed journals. He has played a variety of roles with start-up biotech companies ranging from Principal Investigator to Director of Corporate Development.

Ed KahnRediscovery Life Sciences

Ed is an intellectual property expert and the founding president of EKMS, Inc., a company known for pioneering novel IP management techniques for two decades.

Ed sold EKMS to a publicly traded company in 2004, but came out of retirement to apply his licensing skills and tech transfer experience at CWR, where he will help patients access effective "new" treatments more quickly and affordably through Rediscovery Research™.

The repurposed drugs and other Rediscovery Research approaches established by Cures's research partners are often safer, more effective and cheaper than the current Standard of Care, but there is often a gap between publication of research results and adoption of the "rediscovered" treatment in the clinic by physicians and patients. Ed works with public and private sector life sciences organizations to devise creative new business methods aimed at ensuring that life-saving therapies reach patients as soon as feasible.

Ed has presented and written extensively on licensing and IP strategy for John Wiley, Euromoney Publishing, Forbes, the Wall Street Journal, the Boston Globe, Mass High Tech, the Licensing Executives Society (LES) and the Boston Patent Lawyers' Association. His recent book, "Innovate or Perish: Managing the Enduring Technology Company in the Global Market", focuses on the challenge of IP management in today's evolving innovation environment.

rob metzSenior Vice President, Business Operations and External Affairs, Horizon Pharma

Mr. Metz joined Horizon Pharma in 2009 as the vice president global business operations and general manager Europe. He is responsible for the administration of global business operations and corporate external affairs including patient advocacy. Mr. Metz has over 27 years of commercial, external affairs, finance, administration and operations experience in both small and large pharmaceutical and biotechnology organizations. Prior to joining Horizon Pharma, Mr. Metz’s most recent position was vice president, commercial operations for IDM Pharma who manufactured MEPACT® for pediatric osteosarcoma. Mr. Metz played a key role in the turnaround and eventual sale of IDM Pharma to Takeda Pharmaceuticals in June 2009. He led commercial efforts, including development of key opinion leader and institution center outreach, patient advocacy relations and pricing and reimbursement programming throughout pan-European markets. Prior to joining IDM Pharma, Mr. Metz led commercial operations for NeoPharm, a public rare disease oncology biotechnology company with a phase 3 compound for glioblastoma multiforme.

NorbertRiedelexecportrait2009 011President and Chief Executive Officer, Aptinyx

Dr. Riedel is president and CEO of Aptinyx, as well as a member of the company’s board of directors. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, Dr. Riedel was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Industry Organization.

MichaelRosen

Rosen BioScience Strategies

Michael S. Rosen is Senior Vice President, New Business Development for the Science + Technology Group at Forest City Enterprises, a NYSE-traded national real estate development company which develops and builds bioscience parks across the U.S.  Mr. Rosen works with key research universities affiliated with Forest City bioparks, such as Northwestern University in Chicago, Johns Hopkins University in Baltimore and MIT in Boston, and endeavors to bring life science companies from Europe, Asia, Latin America, India, Israel, and Canada into these parks.

AdriannSax photoEntrepreneur in Residence, Fortress Biotech

Adriann is an Entrepreneur in Residence at Fortress Biotech, a public biotech company which finds and forms subsidiary companies around promising drugs and technologies. For more than 25 years, Adriann has been a global biotech and pharmaceutical industry leader managing all stages of drug development, commercialization, strategic deal-making and partnerships. Prior to Fortress Biotech, Adriann was Executive Vice President, Chief Commercial Officer of Kadmon Corporation leading Kadmon’ s commercial organization, Kadmon Pharmaceuticals, from its inception in September 2010.


Before Kadmon, Adriann was Executive Vice President, Business Development and Strategic Planning at King Pharmaceuticals where she led many profitable transactions in addition to creating and implementing King’s Corporate Strategy for Growth in 2005, contributing to the company’s overall success and ultimate sale to Pfizer in 2011.

eric waehner copyRecordati Rare Diseases

Eric Waehner is the Vice President, Business Development at Recordati Rare Diseases. He has over 25 years of life science industry experience, driving growth strategies and completing transactions across the pharmaceutical, diagnostic and medical device industry segments. Prior to joining Recordati Rare Diseases, he gained experience and contributed to portfolio growth and rationalization at Takeda Pharmaceuticals, Astellas Pharmaceuticals and Abbott Laboratories. Additionally, he gained experience as a consultant with Deloitte and RM Consulting International.

Mr. Waehner received his B.S. in Industrial Engineering from Georgia Tech and his M.B.A from Northwestern University.

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please email susan@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Wednesday the 12th. Copyright 2018 Cures Within Reach.